首页> 美国卫生研究院文献>EBioMedicine >Safety Tolerability and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724 a CBP/β-Catenin Inhibitor in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center Open-Label Dose Escalation Phase 1 Trial

【2h】

Safety Tolerability and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724 a CBP/β-Catenin Inhibitor in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center Open-Label Dose Escalation Phase 1 Trial

机译：抗纤维化小分子PRI-724（一种CBP /β-连环蛋白抑制剂）在丙型肝炎病毒相关性肝硬化患者中的安全性耐受性和初步疗效：单中心开放标签剂量递增的1期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThere is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis.

机译：背景技术目前尚无抗纤维化药物疗法可用于治疗丙型肝炎病毒（HCV）肝硬化。这项研究的目的是评估HCV肝硬化患者中Wnt信号的小分子调节剂PRI-724的安全性，耐受性和抗纤维化作用。

著录项

期刊名称 EBioMedicine
作者
Kiminori Kimura; Akemi Ikoma; Maki Shibakawa; Shinji Shimoda; Kenichi Harada; Masanao Saio; Jun Imamura; Yosuke Osawa; Masamichi Kimura; Koji Nishikawa; Takuji Okusaka; Satoshi Morita; Kazuaki Inoue; Tatsuya Kanto; Koji Todaka; Yoichi Nakanishi; Michinori Kohara; Masashi Mizokami;
展开▼
作者单位

展开▼
年(卷),期 2017(23),-1
年度 2017
页码 79–87
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
PRI-724 Liver cirrhosis HCV Wnt inhibitor;

机译：PRI-724;肝硬化;HCV;Wnt抑制剂;

相似文献

外文文献
中文文献

1. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/@b-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial [J] . Kiminori Kimura, Akemi Ikoma, Maki Shibakawa, EBioMedicine . 2017 ,第169期

机译：抗纤维化小分子PRI-724（一种CBP / @ b-连环素抑制剂）在丙型肝炎病毒相关性肝硬化患者中的安全性，耐受性和初步疗效：单中心，开放标签，剂量递增阶段1试用版
2. Single-Centre, Dose Escalation, Open-Label Phase 1 Trial of the experimental anti-fibrotic small molecule PRI-724 in Patients with Hepatitis C virus related Cirrhosis [J] . Kimura Kiminori, Harada Kenichi, Okusaka Takuji, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016 ,第S1期

机译：单中心，剂量升级，开放标签阶段1试验实验抗纤维化小分子PRI-724在丙型肝炎病毒相关肝硬化患者中
3. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial [J] . Chung Vincent, Mansfield Aaron S., Braiteh Fadi, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017 ,第13期

机译：患有固体瘤患者的LB-100，蛋白质磷酸酶2a抑制剂的安全性，耐受性和初步活性：开放标签，剂量升级，首先 - 人，I期试验
4. A phase I dose‐escalation study to assess safety tolerability pharmacokinetics and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patients with advanced solid tumors or multiple myeloma [O] . Johanna C. Bendell, Robin K. Kelley, Kent C. Shih, -1

机译：I期剂量递增研究评估了双重mTORC1 / mTORC2激酶抑制剂CC-223在晚期实体瘤或多发性骨髓瘤患者中的安全性耐受性药代动力学和初步疗效
5. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial [O] . Kiminori Kimura, Akemi Ikoma, Maki Shibakawa, 2017

机译：抗纤维化小分子pRI-724（一种CBp /β-连环蛋白抑制剂）在丙型肝炎病毒相关性肝硬化患者中的安全性，耐受性和初步功效：单中心，开放标签，剂量递增1期试验

Safety Tolerability and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724 a CBP/β-Catenin Inhibitor in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center Open-Label Dose Escalation Phase 1 Trial

摘要

著录项

相似文献

相关主题

期刊订阅